NDA 020180 · Organon
Proscar
Finasteride · Oral · 5-alpha Reductase Inhibitor
NovelPriority reviewLast checked: Nov 19, 2026Latest source record: Mar 18, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1992
Jun 19, 1992
Approved uses
4
Original approval plus efficacy supplements
Registered trials
78
20 Phase 3, 6 recruiting
FAERS reports
56,555
36,655 serious, 5,077 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Mar 18, 2026.
PROSCAR, is a 5α-reductase inhibitor, indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate to ( 1.1 ): Improve symptoms Reduce the risk of acute urinary retention Reduce the risk of the need for surgery including transurethral resection of the prostate (TURP) and prostatectomy. PROSCAR administered in combination with the alpha-blocker doxazosin is indicated to reduce the risk of symptomatic progression of BPH (a confirmed ≥4 point increase in American Urological Association (AUA) symptom score) ( 1.2 ). Limitations of Use : PROSCAR is not approved for the prevention of prostate cancer ( 1.3 ). 1.1 Monotherapy PROSCAR ® is indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate to: - Improve symptoms - Reduce the risk of acute urinary retention - Reduce the risk of the need for surgery including transurethral resection of the prostate (TURP) and prostatectomy. 1.2 Combination with Alpha-Blocker PROSCAR administered in combination with the alpha-blocker doxazosin is indicated to reduce the risk of symptomatic progression of BPH (a confirmed ≥4 point increase in American Urological Association (AUA) symptom score). 1.3 Limitations of Use PROSCAR is not approved for the prevention of prostate cancer.
Mechanism: The development and enlargement of the prostate gland is dependent on the potent androgen, 5α-dihydrotestosterone (DHT). Type II 5α-reductase metabolizes testosterone to DHT in the prostate gland, liver and skin. DHT induces androgenic effects by binding to androgen receptors in the cell nuclei of these organs. Finasteride is a competitive and specific inhibitor of Type II 5α-reductase with which it slowly forms a stable enzyme complex. Turnover from this complex is extremely slow (t ½ ~ 30 days). This has been demonstrated both in vivo and in vitro . Finasteride has no affinity for the...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Apr 12, 2004 Supplement 26 · Efficacy ReviewLabelLetter
- Mar 20, 1998 Supplement 15 · Efficacy Review
- Mar 20, 1998 Supplement 16 · Efficacy · priority review Review
- Jun 19, 1992 Original approval · Type 1 - New Molecular Entity · priority review Other Important Information from FDA
1 products under this application
- PROSCAR · FINASTERIDE 5MG · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Finasteride" as an intervention, any sponsor and status, largest first.
- Medical Therapy of Prostatic SymptomsPivotal-lookingCompleted
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH
NCT00021814 · 3,407 participants · Start Dec 1995 · Primary completion Nov 30, 2001
Drug: Doxazosin; Finasteride and 2 more · For: Prostatic Hyperplasia; Prostatic Hypertrophy, Benign
Sites: La Jolla, California; Aurora, Colorado; New Haven, Connecticut · 17 sites in all
- Dutasteride Versus Placebo and Finasteride in Men With Androgenetic AlopeciaPivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT01231607 · 917 participants · Start Oct 28, 2010 · Primary completion Feb 1, 2012
Drug: 1mg Finasteride active; 0.02mg dutasteride and 4 more · For: Androgenetic Alopecia
Sites: CABA, Argentina; Ciudad Autonoma de Buenos Aires, Argentina; La Boca, Argentina · 39 sites in all
- A Study of Tadalafil Use With Finasteride in Men With Enlarged Prostates and Urinary SymptomsPivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT01139762 · 696 participants · Start Sep 2010 · Primary completion Feb 2012
Drug: Tadalafil; Placebo and 1 more · For: Benign Prostatic Hyperplasia; Enlarged Prostate
Sites: Davis, California; Fresno, California; Laguna Hills, California · 65 sites in all
- Efficacy and Safety of Combination Therapy Compared With Monotherapy in Patients With Benign Prostatic HyperplasiaPivotal-lookingNot yet recruiting
Il-Yang Pharm. Co., Ltd.Industry
NCT07870759 · 660 participants (planned) · Start Nov 9, 2026 · Primary completion Aug 31, 2027
Drug: Finasteride 5 mg Tablet, single dose; Tamsulosin 0.4Mg Capsule · For: Benign Prostatic Hyperplasia
- A Study of an Investigational Study Drug for Benign Prostatic Hyperplasia (0906-140)Pivotal-lookingCompleted
Organon and CoIndustry
NCT00127179 · 600 participants · Start Jan 1, 2004 · Primary completion Jul 1, 2005
Drug: MK0906, finasteride / Duration of Treatment: 48 weeks; Comparator: placebo / Duration of Treatment: 48 weeks · For: Benign Prostatic Hyperplasia
- Advanced Benefits of Alpha-blocker Monotherapy on Lower Urinary Tracts Symptoms(LUTS) PatientsPivotal-lookingStatus unknown
Seoul National University HospitalAcademic, hospital or other
NCT01736033 · 545 participants · Start Feb 2012 · Primary completion Feb 2017
Drug: Tamsulosin; Finasteride and 1 more · For: Benign Prostate Hyperplasia
Sites: Cheonan, South Korea; Anyang, South Korea; Bucheon-si, South Korea · 11 sites in all
- Study to Evaluate the Efficacy and Safety of P-3074 Topical Solution in the Treatment of Androgenetic AlopeciaPivotal-lookingCompleted
Polichem S.A.Industry
NCT03004469 · 458 participants · Start Aug 2, 2016 · Primary completion Mar 5, 2018
Drug: P-3074; Finasteride and 2 more · For: Alopecia, Androgenetic
Sites: Brussels, Belgium; Ghent, Belgium; Augsburg, Germany · 46 sites in all
- Evaluate the Efficacy and Safety of GV1001 in Patients With Benign Prostatic Hyperplasia (BPH)Pivotal-lookingCompleted
GemVax & KaelIndustry
NCT04032067 · 423 participants · Start Oct 30, 2019 · Primary completion Mar 17, 2022
Drug: GV1001 placebo; Proscar placebo · For: Benign Prostatic Hyperplasia (BPH)
Sites: Guri-si, South Korea; Seongnam-si, South Korea; Gyeongju, South Korea · 23 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- fatigue3,717
- adverse drug reaction2,724
- erectile dysfunction2,620
- depression2,600
- drug ineffective2,431
- diarrhoea2,356
- dizziness2,345
- death2,299
- anxiety2,145
- dyspnoea2,104
- asthenia2,064
- off label use1,981
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 474 |
| 2005 | 527 |
| 2006 | 556 |
| 2007 | 448 |
| 2008 | 520 |
| 2009 | 570 |
| 2010 | 827 |
| 2011 | 1,088 |
| 2012 | 1,319 |
| 2013 | 1,506 |
| 2014 | 1,783 |
| 2015 | 2,803 |
| 2016 | 3,186 |
| 2017 | 3,165 |
| 2018 | 3,770 |
| 2019 | 3,560 |
| 2020 | 4,032 |
| 2021 | 3,416 |
| 2022 | 3,184 |
| 2023 | 3,041 |
| 2024 | 5,048 |
| 2025 | 7,296 |
| 2026 | 4,435 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Proscar (Finasteride)
2024 spending
$406K
Beneficiaries
323
1,210 claims
Per beneficiary
$1,256
$5.07 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $127,269 |
| 2022 | $470,300 |
| 2023 | $458,548 |
| 2024 | $405,645 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- The effectiveness of treatments for androgenetic alopecia: A systematic review and meta-analysis.
Adil A, Godwin M · J Am Acad Dermatol 2017 · Meta-Analysis, Systematic Review
- Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial.
Piraccini BM, Blume-Peytavi U, Scarci F, et al. · J Eur Acad Dermatol Venereol 2022 · Randomized Controlled Trial
- Management of androgenic alopecia: a systematic review of the literature.
Rosenthal A, Conde G, Greco JF, et al. · J Cosmet Laser Ther 2024 · Systematic Review
- Androgenetic alopecia: a review.
Lolli F, Pallotti F, Rossi A, et al. · Endocrine 2017 · Systematic Review
- Adverse Sexual Effects of Treatment with Finasteride or Dutasteride for Male Androgenetic Alopecia: A Systematic Review and Meta-analysis.
Lee S, Lee YB, Choe SJ, et al. · Acta Derm Venereol 2019 · Meta-Analysis, Systematic Review
- Risk of Depression Associated With Finasteride Treatment.
Pompili M, Magistri C, Maddalena S, et al. · J Clin Psychopharmacol 2021 · Meta-Analysis, Systematic Review
Sponsor: Organon
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.